More than 100 civil society organisations and health experts signed on to an open letter yesterday calling out Germany, Sweden, Denmark, the UK and Australia, along with Austria and the United States, as wanting to “derail” and “weaken” the transparency resolution on drug prices and R&D costs. Image Credits: CDDEP. Continue reading ->
This year’s World Health Assembly will provide perhaps the best measure to date of the World Health Organization director-general’s policies since taking office nearly two years ago. But it will also reflect changing times for country relationships and for the state of global health. Image Credits: Photo: WHO/Antoine Tardy, WHO/Antoine Tardy, WHO, WHO/J. D. Kannah. Continue reading ->
A new draft text from an informal consultation at the World Health Organization yesterday shows a North-South divide emerging as member states made changes to the proposed resolution on the transparency of drug prices and the costs of research and development (R&D), brought forward by Italy earlier this year, that is slated for discussion at […] Continue reading ->
Stamping out HIV/AIDS, tuberculosis and malaria can play a major role in helping to achieve universal health coverage (UHC), said a high-level panel of leaders and supporters of the Global Fund to Fight AIDS, Tuberculosis and Malaria, convened yesterday in the lead-up to the World Health Assembly later this month. Image Credits: WHO. Continue reading ->
A number of developed countries are working to delay a landmark proposal at the World Health Organization by Italy to increase transparency of drug prices and R&D costs in an effort to make medicines more affordable, according to sources. The Italian proposal has garnered a number of supporters, including within Europe; but at an informal WHO consultation today and last week at the European Union, countries such as Germany, France, and the United Kingdom have begun pushing for postponement of discussions, sources said. [Now updated with new version of proposal!] Continue reading ->
The first “World Health Assembly Journal” for the upcoming World Health Assembly, 20-28 May, has been published online, together with the provisional agenda for the 72nd WHA and links to some 50 progress reports, strategy plans and updates that will shape the face of the meeting between WHO’s 194 member states. Image Credits: WHO. Continue reading ->
The World Health Organization held an information session with member states and non-state actors last week to present the detailed findings of its 2018 report on cancer medicines pricing. It then posted the 72 detailed slides from the information session on its website. Image Credits: WHO. Continue reading ->
Scientists from a range of countries are calling for an update to World Health Organization guidelines on biosimilar products in order to help national authorities better implement policies to make biosimilars less costly. Current guidelines are outdated and are being misused, they say. But a WHO official told Health Policy Watch the guidelines document should not be made “over-prescriptive”, and that a thorough assessment by an expert group last year found a revision unnecessary but will keep considering it. Continue reading ->
Italy’s Minister of Health spoke out publicly today at a press conference in Rome on the proposed World Health Assembly resolution on drug price transparency, while an open letter published on the Ministry’s website called on other World Health Organization member states to support the initiative. Continue reading ->
Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading ->